Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes

BMC Infectious Diseases

Miriam Tarallo²  Haran T Schlamm³  Xin Gao⁴  Xiang Ji⁴  Jennifer M Stephens⁴  John W Baddley¹ 

[1]Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, 229 Tinsley Harrison Tower, Birmingham, AL, 35294-0006, USA

[2]Pfizer Inc, Rome, Italy

[3]Pfizer Inc, New York, NY, USA

[4]Pharmerit North America LLC, Bethesda, MD, USA

关键词: Hospital costs;    Length of stay;    ICU;    Fluconazole;    Voriconazole;    Aspergillosis;   

Others  :  1158547
DOI  :  10.1186/1471-2334-13-29

 received in 2012-06-29, accepted in 2013-01-15,  发布年份 2013

【 摘 要 】

Background

Few data are available regarding the epidemiology of invasive aspergillosis (IA) in ICU patients. The aim of this study was to examine epidemiology and economic outcomes (length of stay, hospital costs) among ICU patients with IA who lack traditional risk factors for IA, such as cancer, transplants, neutropenia or HIV infection.

Methods

Retrospective cohort study using Premier Inc. Perspective™ US administrative hospital database (2005–2008). Adults with ICU stays and aspergillosis (ICD-9 117.3 plus 484.6) who received initial antifungal therapy (AF) in the ICU were included. Patients with traditional risk factors (cancer, transplant, neutropenia, HIV/AIDS) were excluded. The relationship of antifungal therapy and co-morbidities to economic outcomes were examined using Generalized linear models.

Results

From 6,424 aspergillosis patients in the database, 412 (6.4%) ICU patients with IA were identified. Mean age was 63.9 years and 53% were male. Frequent co-morbidities included steroid use (77%), acute respiratory failure (76%) and acute renal failure (41%). In-hospital mortality was 46%. The most frequently used AF was voriconazole (71% received at least once). Mean length of stay (LOS) was 26.9 days and mean total hospital cost was $76,235. Each 1 day lag before initiating AF therapy was associated with 1.28 days longer hospital stay and 3.5% increase in costs (p < 0.0001 for both).

Conclusions

Invasive aspergillosis in ICU patients is associated with high mortality and hospital costs. Antifungal timing impacts economic outcomes. These findings underscore the importance of timely diagnosis, appropriate treatment, and consideration of Aspergillus as a potential etiology in ICU patients.

【 授权许可】

   
2013 Baddley et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Segal BH: Aspergillosis. N Engl J Med 2009, 360(18):1870-1884.
• [2]Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32(3):358-366.
• [3]Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6):408-415.
• [4]Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E: Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007, 45(2):205-216.
• [5]Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E: Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004, 170(6):621-625.
• [6]Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB: Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 2007, 33(10):1694-1703.
• [7]Verweij PE, Denning DW: The challenge of invasive aspergillosis: increasing numbers in diverse patient groups. Int J Infect Dis 1997, 2:61-63.
• [8]Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E: Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008, 177(1):27-34.
• [9]Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G: Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009, 66(19):1711-1717.
• [10]Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D: Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004, 56(4):269-276.
• [11]Kim A, Nicolau DP, Kuti JL: Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 2011, 54(5):e301-e312.
• [12]Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, Chevrier S, Meunier C, Lebert C, Aupee M, et al.: Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006, 43(5):577-584.
• [13]Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, Iruretagoyena JR, Barcenilla F: Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005, 9(3):R191-199. BioMed Central Full Text
• [14]Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F: Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg 2004, 59(5):251-257.
• [15]Stulberg JJ, Delaney CP, Neuhauser DV, Aron DC, Fu P, Koroukian SM: Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA 2010, 303(24):2479-2485.
• [16]Chang DC, Burwell LA, Lyon GM, Pappas PG, Chiller TM, Wannemuehler KA, Fridkin SK, Park BJ: Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol 2008, 29(1):25-30.
• [17]Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45(6):613-619.
• [18]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
• [19]Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al.: Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005, 9:r191-r199. BioMed Central Full Text
• [20]Lortholary O, Charlemagne A, Bastides F, et al.: A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998–1999. J Antimicrob Chemotherapy 2004, 54:456-64.
• [21]Upton A, Kirby KA, Carpenter P, et al.: Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortatliy. Clin Infect Dis 2007, 44:531-540.
• [22]Auberger J, Lass-Flörl C, Ulmer H, Nogler-Semenitz E, Clausen J, et al.: Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008, 88(5):508-15.
• [23]Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3):327-60.
• [24]MacKenzie EJ, Morris JA, Edelstein SL: Effect of pre-existing disease on length of hospital stay in trauma patients. J Trauma 1989, 29(6):757-65.
• [25]Siegel JH, Shafi S, Goodarzi S, Dischinger PC: A quantitative method for cost reimbursement and length of stay quality assurance in multiple trauma patients. J Trauma 1994, 37(6):928-37.